| 0.82 -0.011 (-1.26%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.06 | 1-year : | 1.24 |
| Resists | First : | 0.91 | Second : | 1.06 |
| Pivot price | 0.78  |
|||
| Supports | First : | 0.79 | Second : | 0.72 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.79 |
| MA(100) : | 0.72 |
MA(250) : | 0.83 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 41.2 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 1.7 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XLO ] has closed below upper band by 22.9%. Bollinger Bands are 2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.85 - 0.85 | 0.85 - 0.86 |
| Low: | 0.8 - 0.81 | 0.81 - 0.81 |
| Close: | 0.81 - 0.82 | 0.82 - 0.83 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Fri, 03 Oct 2025
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - Sahm
Fri, 03 Oct 2025
Xilio Therapeutics Transfers Listing to Nasdaq Capital Market - TipRanks
Thu, 02 Oct 2025
26,000-Share Grant: Xilio Therapeutics Grants Options at $0.8326 Exercise Price - Stock Titan
Tue, 09 Sep 2025
Promising Cancer Drug Shows Partial Responses: Xilio's IL-12 Therapy Advances with $17.5M Gilead Backing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 45.7 (%) |
| Held by Institutions | 25.4 (%) |
| Shares Short | 5,250 (K) |
| Shares Short P.Month | 4,920 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | -177.8 % |
| Return on Assets (ttm) | -31.7 % |
| Return on Equity (ttm) | -277.8 % |
| Qtrly Rev. Growth | 243 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -1.18 |
| PEG Ratio | 0 |
| Price to Book value | 5.85 |
| Price to Sales | 2.83 |
| Price to Cash Flow | -3.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|